Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin vs investigator’s choice chemotherapy in relapsed/refractory CD22-positive ALL
jRCT2080221772Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Pfizer. Started Apr 2012; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2080221772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221772.